Alnylam Pharma Statistics
Alnylam Pharma (DUL) Stock Statistics & Valuation Metrics
Total Valuation
Alnylam Pharma has a market cap or net worth of CHF 16.76B. The enterprise value is CHF 33.47B.
- Market Cap
- CHF 16.76B
- Enterprise Value
- CHF 33.47B
Share Statistics
Alnylam Pharma has 133,937,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 133,937,580
- Owned by Insiders
- 0.24%
- Owned by Institutions
- 75.78%
Financial Efficiency
Alnylam Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 13.74%.
- Return on Equity (ROE)
- 0.40
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 13.74%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 1.49M
- Profits Per Employee
- 125.50K
- Employee Count
- 2,500
- Asset Turnover
- 0.75
- Inventory Turnover
- 8.19
Valuation Ratios
The current PE Ratio of Alnylam Pharma is 7.44. Alnylam Pharma’s PEG ratio is 0.00.
- PE Ratio
- 7.44
- PS Ratio
- 4.05
- PB Ratio
- 5.63
- Price to FCF
- 40.56
- Price to Operating Cash Flow
- 31.20
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Alnylam Pharma had revenue of 3.71B and earned 313.75M in profits. Earnings per share was 2.39.
- Revenue
- 3.71B
- Gross Profit
- 3.04B
- Operating Income
- 501.58M
- Pretax Income
- 323.15M
- Net Income
- 313.75M
- EBITDA
- 631.44M
- Earnings Per Share (EPS)
- 2.39
Cash Flow
In the last 12 months, operating cash flow was 650.37M and capital expenditures -149.64M, giving a free cash flow of 500.73M billion.
- Operating Cash Flow
- 650.37M
- Free Cash Flow
- 500.73M
- Free Cash Flow per Share
- 3.74
Dividends & Yields
Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.47%
- Earnings Yield
- 13.44%
Stock Price Statistics
- Beta
- -0.64
- 52-Week Price Change
- -39.48%
- 50-Day Moving Average
- 187.89
- 200-Day Moving Average
- 201.78
- Relative Strength Index (RSI)
- 5.32
- Average Volume (3m)
- 61
Important Dates
Alnylam Pharma upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Alnylam Pharma as a current ratio of 2.76, with Debt / Equity ratio of 161.99%
- Current Ratio
- 2.76
- Quick Ratio
- 2.71
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.60
- Interest Coverage Ratio
- 1.99
Taxes
In the past 12 months, Alnylam Pharma has paid 9.40M in taxes.
- Income Tax
- 9.40M
- Effective Tax Rate
- 0.03
Enterprise Valuation
Alnylam Pharma EV to EBITDA ratio is 15.86, with an EV/FCF ratio of 39.53.
- EV to Sales
- 3.95
- EV to EBITDA
- 15.86
- EV to Free Cash Flow
- 39.53
- EV to Operating Cash Flow
- 30.43
Balance Sheet
Alnylam Pharma has CHF 3.59B in cash and marketable securities with CHF 1.26B in debt, giving a net cash position of CHF 2.33B billion.
- Cash & Marketable Securities
- CHF 3.59B
- Total Debt
- CHF 1.26B
- Net Cash
- CHF 2.33B
- Net Cash Per Share
- CHF 17.36
- Tangible Book Value Per Share
- CHF 26.93
Margins
Gross margin is 77.28%, with operating margin of 19.50%, and net profit margin of 54.34%.
- Gross Margin
- 77.28%
- Operating Margin
- 19.50%
- Pretax Margin
- 17.08%
- Net Profit Margin
- 54.34%
- EBITDA Margin
- 24.90%
- EBIT Margin
- 23.79%
Analyst Forecast
The average price target for Alnylam Pharma is CHF 254.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 254.54
- Price Target Upside
- 83.68% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 26
- Revenue Growth Forecast
- 48.34%
- EPS Growth Forecast
- 11555.34%
Scores
- Smart Score
- 9
- AI Score
- ―
